Skip to content

GeneLit

Taming the Medical Literature ~ For Genetic Conditions ~ Hand-Curated • Direct to You

  • Home
  • Subscribe to GeneLit
  • Conditions & Syndromes
    • Genetics of Breast & Ovarian Cancer
  • Topics
  • Contact GeneLit
  • Get LitAlerts
  • Terms and Conditions

Home

    • Abiraterone/Olaparib Benefit Is Sustained in Final OS Analysis for mCRPC.
    • Clarke NW, Lovely B.
    • OncLive. 2023 Feb 16.
    • Conference report
    • Free Full Text

    Related:

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2023 Feb 16.)

  • Posted on February 16, 2023February 16, 2023Author Steve KopczakCategories Male Breast Cancer

    Post navigation

    Previous Previous post: LitAlert ~~ GeneLit.com
    Next Next post: Next Post
    Proudly powered by WordPress